Welcome to our dedicated page for ASTRAZENECA PLC SEC filings (Ticker: AZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ASTRAZENECA PLC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ASTRAZENECA PLC's regulatory disclosures and financial reporting.
AstraZeneca PLC reports its current voting share capital. As at 28 February 2026, the company has 1,550,966,708 issued ordinary shares of US$0.25 each with voting rights, and no shares held in treasury. This means the total number of voting rights is 1,550,966,708.
Shareholders can use this total voting rights figure as the denominator when calculating whether they must notify the UK Financial Conduct Authority of holdings or changes in their interest under the Disclosure and Transparency Rules.
AstraZeneca PLC has priced a $2bn global bond offering through its wholly owned subsidiary AstraZeneca Finance LLC. The bonds are issued in three fixed-rate tranches registered with the U.S. SEC and are fully and unconditionally guaranteed by AstraZeneca.
The tranches comprise $0.65bn of notes with a 4.000% coupon maturing on 2 March 2031, $0.60bn with a 4.300% coupon maturing on 2 March 2033, and $0.75bn with a 4.600% coupon maturing on 2 March 2036.
AstraZeneca expects to use the net proceeds for general corporate purposes, which may include refinancing existing debt. The company states that this bond issuance does not impact its financial guidance for 2026.
AstraZeneca PLC has filed its 2025 Annual Report on Form 20-F with the US Securities and Exchange Commission. The report can be viewed on both the SEC website and the company’s own site, giving investors access to detailed audited financial and business information.
The company will provide any security holder with a hard copy of its complete audited financial statements free of charge upon request through its Company Secretary in Cambridge, UK.
AstraZeneca Finance LLC is offering three series of unsecured notes, each fully and unconditionally guaranteed by AstraZeneca PLC. The notes will bear semi-annual interest, be issued in registered book-entry form through DTC and are expected to be listed on the New York Stock Exchange.
The issuer intends to use net proceeds for general corporate purposes, which may include refinancing existing indebtedness. The notes are payable under New York law, may be redeemed (including for certain tax events), and will rank equally with other unsecured, unsubordinated indebtedness of the issuer and guarantor.
AstraZeneca PLC submitted a notice that it has included disclosures required by Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act in its Annual Report on Form 20-F for the year ended December 31, 2025. The company states the disclosure appears under "Item 4.B Business Overview—Disclosures Under the Iran Threat Reduction and Syria Human Rights Act of 2012."
AstraZeneca PLC has filed its Form 20‑F annual report for the year ended 31 December 2025, summarising its global operations, risks and product portfolio. The company lists ordinary shares and multiple long-dated notes on the New York Stock Exchange and reports 1,550,907,927 ordinary shares outstanding at year-end.
The filing incorporates by reference the detailed 2025 Annual Report, while this document highlights extensive risk factors across product development, pricing, supply chain, cybersecurity, AI, legal and sustainability areas. It presents a broad late‑stage pipeline in oncology, cardiovascular, respiratory and rare disease, with numerous Phase III trials and anticipated data readouts beyond 2026.
AstraZeneca also discloses patent expiry ranges for key marketed medicines such as Tagrisso, Imfinzi, Farxiga, Calquence, Ultomiris and others, flagging ongoing generic challenges and potential ‘at risk’ launches. Selected product sales data show Tagrisso at $7,254 million and Farxiga/Forxiga at $6,670 million in 2025, underlining oncology and CVRM as major revenue drivers.
AstraZeneca PLC has published its 2025 Annual Report and Form 20-F information. The report is available on the company’s website and will also be submitted to the UK National Storage Mechanism for public inspection. Printed copies will be sent to shareholders in due course.
The company confirmed that its Annual General Meeting will take place on 9 April 2026. The Annual Report includes key regulated information such as principal risks and uncertainties, the directors’ responsibility statement for the financial statements and directors’ report, and a statement on related party transactions.
AstraZeneca PLC reported upcoming changes to its Board of Directors. Non-Executive Director Nazneen Rahman will retire from the Board at the conclusion of the Company’s AGM on 9 April 2026, after serving since 2017 in several key committee roles.
At the same AGM, Tony Mok will become Chair of the Sustainability Committee and join the Nomination and Governance Committee, while Birgit Conix will join the Sustainability Committee. The company highlights Rahman’s contributions to science, sustainability and governance during her tenure.
AstraZeneca reports that the US Food and Drug Administration approved Calquence (acalabrutinib) plus venetoclax as the first all-oral, fixed-duration combination for adults with chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma in the 1st-line setting.
The 14‑month regimen is supported by the Phase III AMPLIFY trial, where 77% of patients on Calquence plus venetoclax were progression free at three years versus 67% on standard chemoimmunotherapy, and the combo reduced the risk of disease progression or death by 35% (hazard ratio 0.65).
Median progression-free survival was not reached for the Calquence combination versus 47.6 months for chemoimmunotherapy, and safety was consistent with the known Calquence profile without new safety signals.